Crawford Investment Counsel’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$55.9M Sell
1,991,614
-91,017
-4% -$2.42M 0.96% 34
2025
Q4
$51.9M Sell
2,082,631
-72,614
-3% -$1.83M 0.86% 36
2025
Q3
$54.9M Buy
2,155,245
+12,933
+0.6% +$319K 0.91% 36
2025
Q2
$51.9M Sell
2,142,312
-34,646
-2% -$808K 0.91% 37
2025
Q1
$55.2M Buy
2,176,958
+189,933
+10% +$4.97M 0.98% 38
2024
Q4
$52.7M Buy
1,987,025
+141,653
+8% +$3.84M 0.95% 39
2024
Q3
$53.4M Buy
1,845,372
+27,448
+2% +$801K 0.91% 41
2024
Q2
$50.9M Buy
1,817,924
+40,585
+2% +$1.12M 0.97% 38
2024
Q1
$49.3M Buy
1,777,339
+224,802
+14% +$6.24M 0.92% 40
2023
Q4
$44.7M Buy
1,552,537
+129,770
+9% +$3.92M 0.9% 41
2023
Q3
$47.2M Buy
1,422,767
+29,633
+2% +$1.05M 1.02% 39
2023
Q2
$51.1M Buy
1,393,134
+158,417
+13% +$6.17M 1.04% 40
2023
Q1
$50.4M Buy
1,234,717
+612,949
+99% +$26.5M 1.08% 40
2022
Q4
$31.9M Sell
621,768
-10,741
-2% -$515K 0.69% 42
2022
Q3
$27.7M Buy
632,509
+17,695
+3% +$860K 0.65% 43
2022
Q2
$32.2M Buy
614,814
+5,526
+0.9% +$282K 0.71% 42
2022
Q1
$31.5M Sell
609,288
-38,691
-6% -$2.01M 0.61% 42
2021
Q4
$38.3M Sell
647,979
-30,546
-5% -$1.51M 0.73% 43
2021
Q3
$29.2M Sell
678,525
-47,297
-7% -$2.1M 0.6% 44
2021
Q2
$28.4M Buy
725,822
+25,711
+4% +$1,000K 0.57% 44
2021
Q1
$25.4M Buy
700,111
+49,174
+8% +$1.75M 0.57% 45
2020
Q4
$24M Buy
650,937
+29,317
+5% +$1.08M 0.59% 46
2020
Q3
$21.6M Buy
621,620
+69,246
+13% +$2.43M 0.59% 46
2020
Q2
$17.1M Buy
552,374
+78,148
+16% +$2.65M 0.49% 48
2020
Q1
$14.7M Buy
474,226
+359,148
+312% +$12.2M 0.49% 50
2019
Q4
$4.28M Sell
115,078
-4,149
-3% -$148K 0.11% 115
2019
Q3
$4.06M Sell
119,227
-11,829
-9% -$430K 0.11% 106
2019
Q2
$5.39M Sell
131,056
-10,709
-8% -$425K 0.15% 86
2019
Q1
$5.71M Sell
141,765
-55,451
-28% -$2.22M 0.17% 83
2018
Q4
$8.17M Sell
197,216
-241,010
-55% -$10M 0.28% 73
2018
Q3
$18.3M Sell
438,226
-16,235
-4% -$625K 0.56% 47
2018
Q2
$15.6M Sell
454,461
-22,462
-5% -$768K 0.5% 53
2018
Q1
$16.1M Sell
476,923
-3,110
-0.6% -$107K 0.51% 55
2017
Q4
$16.5M Sell
480,033
-1,020
-0.2% -$34.8K 0.51% 56
2017
Q3
$16.3M Buy
481,053
+2,362
+0.5% +$75.9K 0.53% 53
2017
Q2
$15.3M Buy
478,691
+359,636
+302% +$11.3M 0.53% 55
2017
Q1
$3.86M Sell
119,055
-2,069
-2% -$65.2K 0.14% 81
2016
Q4
$3.73M Buy
121,124
+1,016
+0.8% +$31K 0.14% 87
2016
Q3
$3.86M Sell
120,108
-986
-0.8% -$33K 0.14% 84
2016
Q2
$4.04M Sell
121,094
-2,744
-2% -$87.6K 0.16% 79
2016
Q1
$3.48M Sell
123,838
-14,204
-10% -$406K 0.15% 81
2015
Q4
$4.23M Sell
138,042
-5,510
-4% -$173K 0.19% 77
2015
Q3
$4.28M Buy
143,552
+1,870
+1% +$60K 0.19% 75
2015
Q2
$4.51M Sell
141,682
-1,387
-1% -$45.2K 0.17% 77
2015
Q1
$4.72M Buy
143,069
+2,004
+1% +$63.7K 0.17% 73
2014
Q4
$4.17M Sell
141,065
-2,773
-2% -$79.5K 0.15% 78
2014
Q3
$4.04M Sell
143,838
-4,270
-3% -$120K 0.15% 76
2014
Q2
$4.17M Buy
148,108
+12,971
+10% +$370K 0.15% 65
2014
Q1
$4.12M Sell
135,137
-689
-0.5% -$20.5K 0.15% 59
2013
Q4
$3.95M Buy
135,826
+3,130
+2% +$91.1K 0.14% 61
2013
Q3
$3.62M Sell
132,696
-2,317
-2% -$63K 0.14% 62
2013
Q2
$3.59M Buy
+135,013
New +$3.73M 0.15% 57

Other funds holding PFE

Crawford Investment Counsel's PFE Position: Q1 2026 in Review

Crawford Investment Counsel reduced its Pfizer (PFE) stake by 4.4% in Q1 2026, selling an estimated $2.42M and leaving 1,991,614 shares worth $55.9M. The position accounts for 0.96% of the portfolio, ranked #34.

Crawford Investment Counsel first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Crawford Investment Counsel held 1,991,614 shares of Pfizer worth $55.9M as of Q1 2026.
  • Crawford Investment Counsel sold 91,017 Pfizer shares in Q1 2026, an estimated $2.42M.
  • Pfizer made up 0.96% of Crawford Investment Counsel's portfolio in Q1 2026, its #34 holding.
  • Crawford Investment Counsel first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Crawford Investment Counsel's 13F filing for Q1 2026, filed 15 May 2026.